×
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
LON:SBTX

SkinBioTherapeutics Share Forecast, Price & News

GBX 19.26
-0.25 (-1.26%)
(As of 06/30/2022 08:01 AM ET)
Add
Compare
Today's Range
19.26
19.26
50-Day Range
19
30
52-Week Range
17
78.25
Volume
47,408 shs
Average Volume
450,619 shs
Market Capitalization
£30.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SkinBioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SBTX Stock Forecast (MarketRank)

Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
SkinBioTherapeutics logo

About SkinBioTherapeutics (LON:SBTX)

SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

SBTX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
7
Year Founded
N/A

Company Calendar

Last Earnings
3/03/2020
Today
6/29/2022

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£21.95 thousand
Cash Flow
GBX 1.86 per share
Book Value
GBX 2.70 per share

Miscellaneous

Free Float
N/A
Market Cap
£30.19 million
Optionable
Not Optionable
Beta
N/A














SkinBioTherapeutics Frequently Asked Questions

How has SkinBioTherapeutics' stock price performed in 2022?

SkinBioTherapeutics' stock was trading at GBX 42 on January 1st, 2022. Since then, SBTX shares have decreased by 54.2% and is now trading at GBX 19.26.
View the best growth stocks for 2022 here
.

How were SkinBioTherapeutics' earnings last quarter?

SkinBioTherapeutics Plc (LON:SBTX) released its quarterly earnings data on Tuesday, March, 3rd. The company reported ($0.64) EPS for the quarter.
View SkinBioTherapeutics' earnings history
.

Who are SkinBioTherapeutics' key executives?

SkinBioTherapeutics' management team includes the following people:
  • Mr. Stuart John Ashman, CEO & Exec. Director (Age 55, Pay $328.82k)
  • Mr. Douglas John Quinn, Company Sec.
  • Manprit Singh Randhawa, Chief Financial Officer (Age 39)
  • Dr. Catherine O'Neill, Chief Scientific Officer & Member of Scientific Advisory Board

What other stocks do shareholders of SkinBioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SkinBioTherapeutics investors own include Anglo Pacific Group (APF), Avacta Group (AVCT), Inspired (INSE), OptiBiotix Health (OPTI), Lb-shell (LBP), Anglo African Oil & Gas (AAOG), Big Sofa Technologies Group (BST), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES) and Shield Therapeutics (STX).

What is SkinBioTherapeutics' stock symbol?

SkinBioTherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX."

How do I buy shares of SkinBioTherapeutics?

Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is SkinBioTherapeutics' stock price today?

One share of SBTX stock can currently be purchased for approximately GBX 19.26.

How much money does SkinBioTherapeutics make?

SkinBioTherapeutics (LON:SBTX) has a market capitalization of £30.19 million and generates £21.95 thousand in revenue each year.

How many employees does SkinBioTherapeutics have?

SkinBioTherapeutics employs 7 workers across the globe.

How can I contact SkinBioTherapeutics?

SkinBioTherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The official website for SkinBioTherapeutics is www.skinbiotherapeutics.com. The company can be reached via phone at +44-161-4682760.

This page (LON:SBTX) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.